Skin Cancer
- Skin Cancer Risk Is Higher in Patients With Atopic Dermatitis
- Skin Cancer Care Delays Influenced by Low Income, Insurance Barriers
- Personalized ctDNA Monitoring Can Predict Outcomes in Advanced Melanoma
- Positive BRAF Variant Expression is Associated With Improved Melanoma Prognosis
- Neoadjuvant, Adjuvant Pembrolizumab Beneficial in Resectable Melanoma
- Periadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
- Methotrexate Associated With Increased Risk for Skin Cancer
- Nivolumab sBLA Accepted for Patients With Completely Resected Stage IIB, IIC Melanoma
- Cutaneous Immune-Related Adverse Events Improve Survival in Melanoma
- Nivolumab Plus Relatlimab Yields Durable Responses After Progression of Advanced Melanoma
- Personalized Cancer Vaccine + Pembrolizumab Designated Breakthrough Tx for Melanoma
- PAE Effective as Surveillance for Skin Cancer in Childhood Cancer Survivors
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
